CA2219475A1 - Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation - Google Patents

Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Info

Publication number
CA2219475A1
CA2219475A1 CA002219475A CA2219475A CA2219475A1 CA 2219475 A1 CA2219475 A1 CA 2219475A1 CA 002219475 A CA002219475 A CA 002219475A CA 2219475 A CA2219475 A CA 2219475A CA 2219475 A1 CA2219475 A1 CA 2219475A1
Authority
CA
Canada
Prior art keywords
fenofibrate
pharmaceutical composition
biodisponibility
presenting
preparation process
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002219475A
Other languages
English (en)
Other versions
CA2219475C (fr
Inventor
Andre Stamm
Pawan Seth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGP Products Operations GmbH
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9502710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2219475(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to CA002372576A priority Critical patent/CA2372576C/fr
Priority to CA002372561A priority patent/CA2372561A1/fr
Publication of CA2219475A1 publication Critical patent/CA2219475A1/fr
Application granted granted Critical
Publication of CA2219475C publication Critical patent/CA2219475C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet une composition de fénofibrate à libération immédiate comprenant: (a) un support inerte hydrosoluble recouvert d'au moins une couche contenant un principe actif fénofibrate sous forme micronisée une taille inférieure à 20 .mu.m, un polymère hydrophile et éventuellement un tensio-actif; ledit polymère hydrophile représentant au moins 20% en poids du poids de l'élément a); et (b) éventuellement une ou plusieurs phase(s) ou couche(s) externe(s). L'invention a encore pour objet son procédé de préparation.
CA002219475A 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation Expired - Lifetime CA2219475C (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002372576A CA2372576C (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002372561A CA2372561A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9700479A FR2758459B1 (fr) 1997-01-17 1997-01-17 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR9700479 1997-01-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA002372561A Division CA2372561A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002372576A Division CA2372576C (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Publications (2)

Publication Number Publication Date
CA2219475A1 true CA2219475A1 (fr) 1998-07-17
CA2219475C CA2219475C (fr) 2002-07-09

Family

ID=9502710

Family Applications (5)

Application Number Title Priority Date Filing Date
CA002372576A Expired - Lifetime CA2372576C (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002448630A Abandoned CA2448630A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002372561A Abandoned CA2372561A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002219475A Expired - Lifetime CA2219475C (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002448623A Abandoned CA2448623A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CA002372576A Expired - Lifetime CA2372576C (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002448630A Abandoned CA2448630A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA002372561A Abandoned CA2372561A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002448623A Abandoned CA2448623A1 (fr) 1997-01-17 1997-12-11 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Country Status (36)

Country Link
US (18) US6074670A (fr)
EP (6) EP2050445B2 (fr)
JP (6) JP4219988B2 (fr)
KR (2) KR100415897B1 (fr)
CN (2) CN1278678C (fr)
AR (1) AR011411A1 (fr)
AT (4) ATE307576T1 (fr)
BR (1) BR9806738A (fr)
CA (5) CA2372576C (fr)
CY (4) CY2396B1 (fr)
CZ (1) CZ297251B6 (fr)
DE (5) DE69834437T2 (fr)
DK (5) DK1275387T3 (fr)
DZ (1) DZ2398A1 (fr)
EE (1) EE04042B1 (fr)
EG (1) EG23978A (fr)
ES (5) ES2241931T3 (fr)
FR (1) FR2758459B1 (fr)
HK (3) HK1023071A1 (fr)
HU (3) HU227758B1 (fr)
ID (1) ID22528A (fr)
IL (1) IL130790A0 (fr)
IN (1) IN187906B (fr)
IS (1) IS5097A (fr)
MA (1) MA26466A1 (fr)
NO (2) NO329200B1 (fr)
NZ (1) NZ336462A (fr)
PL (1) PL194802B1 (fr)
PT (4) PT952829E (fr)
RU (3) RU2196580C2 (fr)
SK (1) SK285847B6 (fr)
TN (1) TNSN98009A1 (fr)
TR (1) TR199901660T2 (fr)
UA (1) UA61096C2 (fr)
WO (1) WO1998031361A1 (fr)
ZA (1) ZA98324B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037529B2 (en) 1997-01-17 2006-05-02 Laboratoires Fournier Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
ID29270A (id) * 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
CA2270306C (fr) * 1999-04-27 2000-09-26 Bernard Charles Sherman Compositions pharmaceutiques comprenant un melange de fenofibrate microfin
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368620B2 (en) 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7125565B2 (en) * 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
CN1273112C (zh) * 2001-02-22 2006-09-06 斯凯伊药品加拿大公司 具有减少进食－禁食作用的贝特－它汀组合
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
CA2452330C (fr) 2001-07-06 2011-03-22 Lifecycle Pharma A/S Agglomeration controlee
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
CA2474838C (fr) 2002-02-01 2009-01-06 Pfizer Products Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
EP2087882A1 (fr) * 2002-03-26 2009-08-12 Teva Pharmaceutical Industries Ltd. Microparticules de médicament
EP2228060A1 (fr) * 2002-05-03 2010-09-15 Skyepharma Canada Inc. Formes galéniques orales comportant du fénofibrate
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
EP1539117A4 (fr) * 2002-06-28 2005-12-14 Shire Lab Inc Formulations a base de fenofibrate et/ou de derives de fenofibrate ayant une biodisponibilite orale amelioree
EP2295529B2 (fr) * 2002-07-11 2022-05-18 Basf As Procédé de diminution des polluants environnementaux dans une huile ou une graisse et produit d'alimentation pour poissons
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
AU2003263480A1 (en) * 2002-09-24 2004-04-19 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
EP1569515A4 (fr) * 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa Methodes de vaccination contre le paludisme
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
CN100367947C (zh) * 2002-12-04 2008-02-13 徐州恩华赛德药业有限责任公司 具有抗高血脂症的含非诺贝特的药物组合物
ATE411010T1 (de) 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
ATE359777T1 (de) * 2002-12-17 2007-05-15 Abbott Gmbh & Co Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
DE102004002761B4 (de) * 2004-01-20 2017-01-05 Daimler Ag Verfahren zum Betrieb eines Antriebsstrangs eines Kraftfahrzeugs
EP1559419A1 (fr) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir
EP1568369A1 (fr) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Utilisation du meloxicam pour le traitement de maladies respiratoires des porcs
FR2868079B1 (fr) * 2004-03-29 2007-06-08 Seppic Sa Tensioactifs sous forme de poudre utilisables dans des comprimes ou des gelules procede de preparation et compositions les contenant
US7244765B2 (en) 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
EP1827416A1 (fr) * 2004-12-03 2007-09-05 Abbott Laboratories Compositions pharmaceutiques
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
WO2006062933A2 (fr) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Compositions stables de fenofibrate comprenant des esters d'acides gras
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
CA2593191A1 (fr) * 2005-01-14 2006-07-20 Avax Technologies, Inc. Methode de production d'un vaccin pour le traitement du cancer
BRPI0606187A2 (pt) * 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
JP2006273849A (ja) * 2005-03-02 2006-10-12 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
CN101208083A (zh) * 2005-03-08 2008-06-25 瑞莱恩特医药品有限公司 利用他汀和Omega-3脂肪酸治疗及其组合产品
CA2600407A1 (fr) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Preparations ameliorees a base de fenofibrate
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1707197A1 (fr) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Compositions, contenant du fenofibrate et un mélange d'agents tensio-actifs
AU2005330266A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or PEG/poloxamer
US20070185199A1 (en) * 2005-04-08 2007-08-09 Ju Tzuchi R Pharmaceutical formulations
EP1868587A2 (fr) 2005-04-08 2007-12-26 Abbott Laboratories Formulation pharmaceutique comprenant de l'acide fenofibrique et/ou de ses sels
US20070148234A1 (en) * 2005-04-08 2007-06-28 Ju Tzuchi R Pharmaceutical formulations
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
WO2007011349A1 (fr) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Nouveau procede de granulation et granule produit par ce procede
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1785133A1 (fr) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
DK1803441T3 (da) 2005-12-28 2009-08-03 Teva Pharma Farmaceutiske fenofibrat-formuleringer, der har forbedret biotilgængelighed
BRPI0520821A2 (pt) * 2005-12-28 2009-06-30 Teva Pharma formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
JP2009537478A (ja) * 2006-05-13 2009-10-29 ノヴォ ノルディスク アクティーゼルスカブ レパグリニドとメトホルミンを含む錠剤配合物
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP2452683A3 (fr) 2006-06-26 2012-08-22 Amgen Inc. Procédés pour le traitement de l'athérosclérose
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20100034888A1 (en) * 2006-09-15 2010-02-11 Hubert Clemens Pellikaan Granulate containing a pharmaceutically active substance and method for its manufacture
CA2664315C (fr) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Unite posologique pour administration sublinguale, buccale ou orale de substances actives pharmaceutiques insolubles dans l'eau
AU2007313018A1 (en) * 2006-10-13 2008-04-24 Janssen Pharmaceutica N.V. Phenylalkyl carbamate compositions
US20110097414A1 (en) * 2007-02-26 2011-04-28 Sandal Roshan Lal Pharmaceutical compositions comprising adsorbate of fenofibrate
MX2009006114A (es) * 2007-03-02 2009-11-10 Meda Pharmaceuticals Inc Composiciones que comprenden carisoprodol y metodos de uso de las mismas.
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
KR20100040937A (ko) 2007-07-26 2010-04-21 암젠 인크 변형된 레시틴-콜레스테롤 아실트랜스퍼라제 효소
US20100285126A1 (en) * 2007-08-02 2010-11-11 Rahul Dabre Pharmaceutical compositions of fenofibrate
AU2008303129B2 (en) * 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
KR101569227B1 (ko) 2008-03-11 2015-11-13 아스카 세이야쿠 가부시키가이샤 고체 분산체와 그 의약 조성물, 그리고 그들의 제조 방법
MX2011006307A (es) * 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
FR2940118B1 (fr) 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
US8501759B2 (en) 2009-01-02 2013-08-06 Fournier Laboratories Ireland Limited Use of fibrates
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010092925A1 (fr) * 2009-02-12 2010-08-19 あすか製薬株式会社 Dispersion solide, composition pharmaceutique comprenant celle-ci et procédés de production de la dispersion solide et de la composition pharmaceutique
AU2010253578B2 (en) 2009-05-27 2014-01-30 Samyang Biopharmaceuticals Corporation A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
KR100980752B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
KR101202994B1 (ko) 2010-04-12 2012-11-21 한미사이언스 주식회사 페노피브린산 및 알칼리화제를 포함하는 경구용 약학 조성물
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US10192644B2 (en) 2010-05-11 2019-01-29 Lightbridge Corporation Fuel assembly
WO2011143172A1 (fr) 2010-05-11 2011-11-17 Thorium Power, Inc. Assemblage de combustible à noyau d'alliage de combustibles métalliques et son procédé de fabrication
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201118182D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2013064853A1 (fr) 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Compositions pharmaceutiques orales à dose réduite de fénofibrate
CA2858572C (fr) 2011-12-08 2023-01-17 Amgen Inc. Proteines liant un antigene lcat humain et leur utilisation en therapie
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (fr) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Compositions pharmaceutiques à dose réduite de fénofibrate
EP2842547A1 (fr) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Compositions de fénofibrate améliorées
CA2924827C (fr) 2013-09-18 2023-01-03 Georgetown University Traitement d'une maladie neurodegenerative au moyen de fenofibrate et de ses analogues
KR101576587B1 (ko) * 2014-02-05 2015-12-10 한양대학교 에리카산학협력단 신규한 페노피브레이트 함유 젤라틴 나노입자
PL3154528T3 (pl) 2014-06-11 2023-07-10 SpecGx LLC Suszone rozpyłowo kompozycje o różnych profilach rozpuszczania i sposoby ich wytwarzania
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CN104352466A (zh) * 2014-11-17 2015-02-18 辰欣药业股份有限公司 一种非诺贝特组合物及其制剂
CN104922078B (zh) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
CN107049981A (zh) * 2017-04-11 2017-08-18 深圳市泛谷药业股份有限公司 一种速释氨磺必利药物组合物及其制备方法
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CA3094431C (fr) * 2018-03-19 2023-06-27 Taiho Pharmaceutical Co., Ltd. Composition pharmaceutique comprenant du sulfate d'alkyle de sodium
BR112022001514A2 (pt) 2019-07-31 2022-03-22 Intas Pharmaceuticals Ltd Composição farmacêutica multicamada e processo para a preparação de uma composição farmacêutica
EP3943071A1 (fr) 2020-03-31 2022-01-26 Zurab Durmischchanowitch Khinikadze Composition contenant des composés lipophiles naturels, utilisation de la composition et procédé de préparation de la composition
WO2022071768A1 (fr) * 2020-09-29 2022-04-07 Addpharma Inc. Composition pharmaceutique comprenant des particules de fénofibrate à biodisponibilité améliorée
WO2024058848A1 (fr) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Compositions pharmaceutiques de roflumilast et de solvants capables de dissoudre des quantités élevées de médicament

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9496A (en) * 1852-12-21 Method of measuring cloth on the cloth-beam
US114839A (en) * 1871-05-16 Improvement in apparatus for aerating beer-barrels
US104060A (en) * 1870-06-07 Improvement in organ-bellows
US57998A (en) * 1866-09-11 Improvement in broom-heads
US58004A (en) * 1866-09-11 Improved lap-joint for belting
US58005A (en) * 1866-09-11 Improvement in distilling petroleum and other liquids
US168413A (en) * 1875-10-05 Improvement in hydrants
US104051A (en) * 1870-06-07 Improvement in handles of sheet-metal spoons, forks
US5783A (en) * 1848-09-19 Spinoabdominal supporter
US57999A (en) * 1866-09-11 Improved composition for roofing
US57997A (en) * 1866-09-11 Improvement in malt-ksln floors
US6655A (en) * 1849-08-21 Eirepboof safe
US92597A (en) * 1869-07-13 Improved counterpoise gun-carriage
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US2776996A (en) * 1955-12-22 1957-01-08 Du Pont Manufacture of beta-methylmercaptopropionaldehyde
CH543472A (fr) 1969-01-31 1973-10-31 Orchimed Sa Procédé pour la préparation d'acides phénoxyalcoyl-carboxyliques
FR2314917A1 (fr) * 1975-06-20 1977-01-14 Rhone Poulenc Ind Procede de fabrication de l'aldehyde beta-methylthiopropionique
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
ATE5852T1 (de) 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2494112B1 (fr) * 1980-11-19 1986-01-10 Laruelle Claude
DE3107933A1 (de) * 1981-03-02 1982-09-16 Cassella Ag, 6000 Frankfurt Substituierte 3-amino-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4463743A (en) * 1981-12-14 1984-08-07 Brunswick Corporation Capacitor discharge ignition system for internal combustion engines
FR2532706B1 (fr) * 1982-09-07 1987-04-30 Renault Dispositif d'amortissement et vibrations d'un coupleur elastique en milieu humide, en particulier pour convertisseur de couple
DE3247118A1 (de) * 1982-12-20 1984-06-20 Cassella Ag, 6000 Frankfurt Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
FR2557459B1 (fr) * 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
IT1180507B (it) * 1984-06-29 1987-09-23 Roberto Valducci Procedimento per la preparazione di etofibrato o sostanze di pari o simili caratteristiche, in microgunuli-ritardo e prodotto ottenuto con tale procedimento
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
EP0179583A1 (fr) 1984-10-04 1986-04-30 Merck & Co. Inc. Système pour augmenter la vitesse de dissolution dans l'eau et la solubilité de médicaments peu solubles
US4649082A (en) 1985-03-07 1987-03-10 Ppg Industries, Inc. Radiation curable compositions based on radiation curable esters of polyfunctional hydroxyl-containing carboxylic acids
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US4859703A (en) * 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US4961891A (en) * 1988-10-04 1990-10-09 Garlock, Inc. Method of making high compressibility gasket material
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
GB9015872D0 (en) * 1990-07-19 1990-09-05 Secr Defence Production of ceramic filaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
US5905171A (en) * 1995-06-22 1999-05-18 Novus International, Inc. Process for the preparation of 3-(methylthio)propanal
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
FR2723586A1 (fr) 1994-08-11 1996-02-16 Seth Pawan Nouvelles compositions contenant de la cimetidine et associations en derivant
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE69631834T2 (de) * 1995-09-21 2005-02-10 Pharma Pass Ii Llc, Irvine Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
DE19608750A1 (de) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5952396A (en) * 1997-06-16 1999-09-14 Raychem Corporation Low modulus elastomer
CA2214895C (fr) * 1997-09-19 1999-04-20 Bernard Charles Sherman Composition pharmaceutique amelioree comprenant du fenofibrate
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6334192B1 (en) * 1998-03-09 2001-12-25 Ronald S. Karpf Computer system and method for a self administered risk assessment
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
GB2363866B (en) * 2000-05-31 2002-11-06 Intamission Ltd Data processing apparatus, method and system
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DE60138658D1 (de) * 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
CA2456732C (fr) * 2001-08-07 2012-10-30 Galephar M/F Composition pharmaceutique orale contenant une combinaison de ppar.alpha. et d'un inhibiteur de l'hmg-coa reductase
DE60210626T2 (de) 2001-08-07 2007-03-15 Laboratoires Smb Sa Verbesserte pharmazeutische zusammensetzung mit einem ppar-alpha-mittel und verfahren zu ihrer herstellung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037529B2 (en) 1997-01-17 2006-05-02 Laboratoires Fournier Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US7041319B2 (en) 1997-01-17 2006-05-09 Laboratoires Fournier Fenofibrate pharmaceutical composition having high bioavailabilty
US8329214B2 (en) 1997-01-17 2012-12-11 Laboratoires Fournier S.A. Process for producing fenofibrate tablets
US8343540B2 (en) 1997-01-17 2013-01-01 Laboratories Fournier S.A. Process for producing fenofibrate tablets

Also Published As

Publication number Publication date
TNSN98009A1 (fr) 2005-03-15
EP2050445B1 (fr) 2013-06-26
CZ297251B6 (cs) 2006-10-11
PL334748A1 (en) 2000-03-13
EP2050445A2 (fr) 2009-04-22
US20030104051A1 (en) 2003-06-05
IS5097A (is) 1999-06-29
NO993519D0 (no) 1999-07-16
DE69829591T2 (de) 2006-02-09
ATE324885T1 (de) 2006-06-15
US20030104060A1 (en) 2003-06-05
DE69811855D1 (de) 2003-04-10
EP2050445B2 (fr) 2021-07-21
ES2241931T3 (es) 2005-11-01
WO1998031361A1 (fr) 1998-07-23
US6652881B2 (en) 2003-11-25
RU2002109746A (ru) 2004-03-20
NO993519L (no) 1999-09-16
JP4943975B2 (ja) 2012-05-30
EP0952829A1 (fr) 1999-11-03
DK0952829T3 (da) 2003-06-23
EP1273294B1 (fr) 2005-10-26
CY2513B1 (en) 2005-12-23
RU2196580C2 (ru) 2003-01-20
FR2758459B1 (fr) 1999-05-07
FR2758459A1 (fr) 1998-07-24
CA2372561A1 (fr) 1998-07-17
JP4365343B2 (ja) 2009-11-18
DK1273293T3 (da) 2005-06-27
US20020114839A1 (en) 2002-08-22
US20020009496A1 (en) 2002-01-24
DE69832108T2 (de) 2006-09-21
DK1275387T3 (da) 2006-08-28
US20080063726A1 (en) 2008-03-13
ES2263714T3 (es) 2006-12-16
US20040057999A1 (en) 2004-03-25
EE04042B1 (et) 2003-06-16
JP2009143967A (ja) 2009-07-02
BR9806738A (pt) 2000-02-29
SK285847B6 (sk) 2007-09-06
DE69834437D1 (de) 2006-06-08
US7037529B2 (en) 2006-05-02
US20040057998A1 (en) 2004-03-25
CZ253599A3 (cs) 1999-11-17
EP1273293A1 (fr) 2003-01-08
PT1273293E (pt) 2005-06-30
CY2560B1 (fr) 2008-07-02
JP2009120623A (ja) 2009-06-04
DK1273294T3 (da) 2006-03-13
ES2427252T5 (es) 2022-02-14
ES2427252T3 (es) 2013-10-30
US20040058005A1 (en) 2004-03-25
AR011411A1 (es) 2000-08-16
US8329214B2 (en) 2012-12-11
ATE233556T1 (de) 2003-03-15
MA26466A1 (fr) 2004-12-20
KR100391104B1 (ko) 2003-07-12
SK96299A3 (en) 2000-08-14
CY2396B1 (en) 2004-09-10
PL194802B1 (pl) 2007-07-31
NZ336462A (en) 2000-09-29
ZA98324B (en) 1998-08-12
EP0952829B1 (fr) 2003-03-05
RU2238089C2 (ru) 2004-10-20
DE69834437T2 (de) 2006-11-16
EP2050445A3 (fr) 2009-09-09
EP1273294A1 (fr) 2003-01-08
US6596317B2 (en) 2003-07-22
EP1273293B1 (fr) 2005-03-30
US20040092597A1 (en) 2004-05-13
HU228849B1 (hu) 2013-06-28
HUP0000808A3 (en) 2001-02-28
ES2195308T3 (es) 2003-12-01
US20080064759A1 (en) 2008-03-13
CN1278678C (zh) 2006-10-11
IN187906B (fr) 2002-07-20
JP4219988B2 (ja) 2009-02-04
US20040057997A1 (en) 2004-03-25
US20040058004A1 (en) 2004-03-25
US6277405B1 (en) 2001-08-21
DK2050445T3 (da) 2013-09-08
TR199901660T2 (xx) 1999-09-21
ATE291911T1 (de) 2005-04-15
ATE307576T1 (de) 2005-11-15
ID22528A (id) 1999-10-28
KR20000070021A (ko) 2000-11-25
US8343540B2 (en) 2013-01-01
JP2005206614A (ja) 2005-08-04
KR100415897B1 (ko) 2004-01-24
US20070190136A1 (en) 2007-08-16
IL130790A0 (en) 2001-01-28
US6074670A (en) 2000-06-13
ES2254569T3 (es) 2006-06-16
EP1468681A1 (fr) 2004-10-20
CA2219475C (fr) 2002-07-09
AU5336798A (en) 1998-08-07
HK1131051A1 (en) 2010-01-15
US6589552B2 (en) 2003-07-08
UA61096C2 (uk) 2003-11-17
US20090035379A1 (en) 2009-02-05
US7041319B2 (en) 2006-05-09
CA2372576C (fr) 2004-02-10
CN1496738B (zh) 2011-03-30
DE69811855T2 (de) 2003-12-18
DK2050445T4 (da) 2021-10-18
HK1065952A1 (en) 2005-03-11
EP1275387B1 (fr) 2006-05-03
CA2372576A1 (fr) 1998-07-17
EE9900296A (et) 2000-02-15
CY2547B1 (fr) 2008-07-02
HUP0000808A2 (hu) 2000-12-28
PT2050445E (pt) 2013-08-23
PT1275387E (pt) 2006-08-31
EP1275387A1 (fr) 2003-01-15
JP2007326878A (ja) 2007-12-20
EG23978A (fr) 2008-02-26
HU0400409D0 (hu) 2004-04-28
AU731964B2 (en) 2001-04-05
DE29825080U1 (de) 2004-11-04
RU2236850C2 (ru) 2004-09-27
US20070184103A1 (en) 2007-08-09
DZ2398A1 (fr) 2003-06-04
NO20100034L (no) 1999-09-16
HU230685B1 (en) 2017-08-28
JP2011173927A (ja) 2011-09-08
HK1023071A1 (en) 2000-09-01
CA2448623A1 (fr) 1998-07-17
PT952829E (pt) 2003-07-31
US20020168413A1 (en) 2002-11-14
CN1496738A (zh) 2004-05-19
HU227758B1 (hu) 2012-02-28
DE69832108D1 (de) 2005-12-01
DE69829591D1 (de) 2005-05-04
JP2001511156A (ja) 2001-08-07
CN1243438A (zh) 2000-02-02
CA2448630A1 (fr) 1998-07-17
NO329200B1 (no) 2010-09-13

Similar Documents

Publication Publication Date Title
CA2219475A1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
CA2219698A1 (fr) Preparation a liberation prolongee
CA2161004A1 (fr) Bande avec ingredient actif
CA2232310A1 (fr) Compositions stables contenant du n-propargyl-1-aminoindane
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
CA2213861A1 (fr) Procede de chargement de vesicules de lipides
CA2004598A1 (fr) Aerosols medicinaux
CA2322875A1 (fr) Chewing-gum enrobe, son procede de preparation et utilisation d'une ou de plusieurs substances actives solides
EP1690530A3 (fr) Composition pharmaceutique à libération prolongée sans effet alimentaire et procédé pour diminuer l'effet alimentaire dans la liberation de principes actifs
CA2154424A1 (fr) 1-phenyl-3-dimethylaminopropane possedant des proprietes pharmaceutiques
CA2290017A1 (fr) Procede pour produire des formes galeniques solides pouvant etre administrees par voie orale, a liberation de principe actif controlee
CA2274565A1 (fr) Compositions aqueuses a base d'alcool utilisees dans l'administration transdermique d'agents pharmaceutiques
WO2001089479A3 (fr) Compositions pharmaceutiques a liberation prolongee destinees a l'administration par voie parenterale de composes hydrophiles biologiquement actifs
EP1468679A3 (fr) Composition de tramadol à libération contrôlée
IE880281L (en) Swellable pellets
EP0983995A3 (fr) Composés diméthyl-(3-aryl-but-3-ènyl)-amine pharmaceutiquement actifs
CA2161103A1 (fr) Formulations d'oxybutynine a liberation regulee
CA2159580A1 (fr) Compositions pharmaceutiques renfermant la polyvinylpyrrolidone et un tri-ester; methode de preparation
CA2213996A1 (fr) Formes galeniques par voie orale comprenant un inhibiteur de la pompe a protons et un agent antiacide ou un alginate
CA2354034A1 (fr) Compositions contenant un peptide et un acide polylactique-glycolique concues pour la preparation d'implants sous-cutanes avec duree de liberation prolongee
MX9500159A (es) Preparacion farmaceutica percutanea.
EP0103387A3 (fr) Formulations de comprimés à action prolongée du type matrice

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20171211

MKEX Expiry

Effective date: 20171211